078160 — Medipost Co Share Price
0.000.00%
Last trade - 00:00- KR₩293bn
- KR₩272bn
- KR₩71bn
- 14
- 17
- 43
- 10
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.19 | ||
| Price to Tang. Book | 1.21 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.25 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -19.83% | ||
| Return on Equity | -22.22% | ||
| Operating Margin | -93.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 48,624.82 | 54,856.21 | 64,200.63 | 68,642.99 | 70,657.03 | n/a | n/a | 9.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Medipost Co Ltd is a Korea-based company primarily engaged in the cord blood banking business. The Company operates through four segments. The Cord Blood Banking segment operates cord blood storage and hematopoietic stem cell transplantation. The Stem Cell Treatment segment operates allogeneic stem cell treatment production as well as contract development and manufacturing organization (CDMO) of cell gene treatment. The Health Functional Food segment provides multivitamins and mineral health functional foods. The Other segment operates leasing business.
Directors
- Dong Jin Hwang PRE (51)
- Yun Seon Yang CEO (48)
- Jang Won Lee VPR (47)
- Won Yil Oh VPR (50)
- Jang Yeong Lee MDR (45)
- Hong Gu Kim DRC (51)
- Jin Heon Kim DRC (51)
- Hyeon Gi Min NID (48)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 26th, 2000
- Public Since
- July 29th, 2005
- No. of Shareholders
- 22,119
- No. of Employees
- 209
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 34,098,785
- Address
- 21, SEONGNAM, 13494
- Web
- https://www.medi-post.co.kr/
- Phone
- +82 234656677
- Auditors
- Crowe LLP
Upcoming Events for 078160
Q2 2025 Medipost Co Ltd Earnings Release
Similar to 078160
3Billion
Korea Exchange - KOSDAQ
ABion
Korea Exchange - KOSDAQ
ABL Bio
Korea Exchange - KOSDAQ
Amicogen
Korea Exchange - KOSDAQ
AprilBio Co
Korea Exchange - KOSDAQ
FAQ
What is the Medipost Co share price?
As of Today at 21:59 UTC, shares in Medipost Co are trading at KR₩8,800. This share price information is delayed by 15 minutes.
How has the Medipost Co share price performed this year?
Shares in Medipost Co last closed at KR₩8,800 and the price had moved by +24.19% over the past 365 days. In terms of relative price strength the Medipost Co share price has outperformed the FTSE Developed Asia Pacific Index by +25.61% over the past year.
What are the analyst and broker recommendations for Medipost Co?
There is no consensus recommendation for this security.
Find out moreWhat is the Medipost Co dividend yield?
Medipost Co does not currently pay a dividend.
Does Medipost Co pay a dividend?
Medipost Co does not currently pay a dividend.
When does Medipost Co next pay dividends?
Medipost Co does not currently pay a dividend.
How do I buy Medipost Co shares?
To buy shares in Medipost Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medipost Co?
As of the previous close price of KR₩8,800, shares in Medipost Co had a market capitalisation of KR₩293bn.
Where are Medipost Co shares listed?
Here are the trading details for Medipost Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 078160
What kind of share is Medipost Co?
Based on an overall assessment of its quality, value and momentum Medipost Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medipost Co share price forecast for 2025?
The analyst consensus target price for shares in Medipost Co is KR₩538. That is 93.89% below the last closing price of KR₩8,800.
Analysts covering Medipost Co currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Medipost Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medipost Co. Over the past six months, its share price has outperformed the FTSE Developed Asia Pacific Index by +41.39%.
As of the last closing price of KR₩8,800, shares in Medipost Co were trading +7.09% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medipost Co PE Ratio?
The Medipost Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩8,800.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medipost Co?
Medipost Co's management team is headed by:
- Dong Jin Hwang - PRE
- Yun Seon Yang - CEO
- Jang Won Lee - VPR
- Won Yil Oh - VPR
- Jang Yeong Lee - MDR
- Hong Gu Kim - DRC
- Jin Heon Kim - DRC
- Hyeon Gi Min - NID